AN2 Therapeutics (ANTX) director reports gift of 405,880 shares and 145,538 held
Rhea-AI Filing Summary
AN2 Therapeutics director Joseph S. Zakrzewski reported a bona fide gift of 405,880 shares of common stock. The gifted shares were held indirectly through the Z3 Trust, and he disavows beneficial ownership of those shares. Following this transaction, he reports 145,538 shares of AN2 Therapeutics common stock held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 405,880 shares
Net Sell
2 txns
Insider
Zakrzewski Joseph S
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Gift | Common Stock F1, F2 | 405,880 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 0 shares (Indirect, See footnote);
Common Stock — 145,538 shares (Direct)
Footnotes (2)
- F1. Reflects a gift of shares to the children of the Reporting Person.
- F2. The shares are held by Nancy Zakrzewski TTEE Z3 Trust U/A DTD 11/25/14 ("Z3 Trust"). The Reporting Person disavows beneficial ownership of the shares held by Z3 Trust.
Key Figures
Shares gifted: 405,880 shares
Gift price per share: $0.0000
Indirect shares after gift: 0 shares
+2 more
5 metrics
Shares gifted
405,880 shares
Bona fide gift of common stock to the children of the reporting person
Gift price per share
$0.0000
Reported transaction price per share for the gifted common stock
Indirect shares after gift
0 shares
Total indirect holdings following the gift from Z3 Trust
Direct shares after transaction
145,538 shares
Directly held AN2 Therapeutics common stock after the reported transactions
Gift transactions count
1
Number of bona fide gift transactions reported in this Form 4
Key Terms
bona fide gift, beneficial ownership, indirect ownership, Rule 10b5-1
4 terms
bona fide gift financial
"Transaction code G is described as a bona fide gift"
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
beneficial ownership financial
"The Reporting Person disavows beneficial ownership of the shares held"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
indirect ownership financial
"The shares are held by Z3 Trust and reported as indirect ownership"
Rule 10b5-1 regulatory
"A document-level Rule 10b5-1 checkbox is provided but not checked"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
FAQ
What insider transaction did AN2 Therapeutics (ANTX) director Joseph S. Zakrzewski report?
Joseph S. Zakrzewski reported a bona fide gift of 405,880 shares of AN2 Therapeutics common stock. The shares were transferred as a gift and not sold for cash consideration, according to the disclosure.
What are Joseph S. Zakrzewski’s AN2 Therapeutics (ANTX) holdings after the reported gift?
After the reported gift, he reports 145,538 shares of AN2 Therapeutics common stock held directly. The indirect position tied to the Z3 Trust is reported as 0 shares following the gift transaction.
Did Joseph S. Zakrzewski use a Rule 10b5-1 trading plan for this AN2 Therapeutics (ANTX) transaction?
The filing’s Rule 10b5-1 checkbox is not checked, and there is no footnote indicating use of a trading plan. The gift of 405,880 shares is therefore not described as made under a 10b5-1 plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
